Key Points
-
Merck is coming off a strong quarter as revenue from a new version of Keytruda boosted its top line.
-
It remains likely, however, that its revenue will drop off in the near future as key patents on Keytruda are expiring in the near future.
-
The cancer drug accounts for close to half of Merck’s total revenue.
-
It’s been a tremendous year for drugmaker Merck (NYSE:MRK), whose shares have soared by nearly 40% thus far in 2026, performing far better than the broader market, as the S&P 500 has risen by just under 9%.
Merck hit a new all-time high of nearly $157 earlier this year. While it’s come down from those levels, it’s not far from its peak. Is this top healthcare stock still a good buy at around $150, or has it gotten too expensive?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
Why investors have become more bullish on Merck of late
The big concern around Merck in recent years has been that, as strong as its top cancer drug Keytruda has been, forward-looking investors worry about where the company’s future growth will come from as key patents on the drug expire in 2028.
Merck, however, has launched a new version of the drug, which is a subcutaneous (under-the-skin) injection, called Keytruda Qlex. The company hopes that this will help it continue to generate revenue from Keytruda even after the loss of exclusivity for its original intravenous formulation.
Revenue for Keytruda in the third quarter (which went up until the end of September) was stronger than analysts expected, coming in at $8.6 billion, which included $830 million from Qlex. It has given investors hope that the company’s Keytruda sales might not nosedive as sharply as previously feared as generics enter the market in the near future.
There is, nonetheless, still some risk with the stock. For investors, it may come down to how much of a discount is justifiable.
Is the stock likely to head higher?
Keytruda is a massive part of Merck’s business, accounting for close to half of its revenue in Q3. The outlook for the drug will have a drastic impact on the overview for the overall business and how its stock might perform.
Once generics are available in the market, there will inevitably be some drop in revenue; it’s a matter of how significant it will be. That’s the big question right now, and why some sort of discount is warranted.
Currently, Merck’s stock trades at a forward price-to-earnings (P/E) multiple of 16, which is based on analyst expectations of future earnings. The S&P 500 averages a forward P/E multiple of less than 19. There’s a bit of a discount for Merck’s stock, but it isn’t a big one.
While the business is doing well and the stock has been surging this year, I’d hold off on buying it because, at this level, it may have more downside risk than potential upside.
Should you buy stock in Merck right now?
Before you buy stock in Merck, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Merck wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*
Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 16, 2026.
David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck. The Motley Fool has a disclosure policy.